Reversible mental deterioration and neurological disturbances with o,p'-DDD therapy.
A patient with serious neurological and neuropsychological side-effects of a 2-year treatment with 1,1-dichloro-(o-chlorophenyl)-2-(p-chlorophenyl)ethane (o,p'-DDD) for adrenal carcinoma showed complete recovery after discontinuation of the drug. Studying a larger number of patients during and after long term treatment with o,p'-DDD is indicated. If results of this report are confirmed, therapy should not be discontinued even if serious side effects occur.
Bollen
E
E
Department of Neurology, University Hospital, Leiden, The Netherlands.
Lanser
J B
JB
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy* / Q000601:surgery; D000328:Adult; D002524:Cerebellar Ataxia / Q000139:chemically induced / Q000175:diagnosis; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007360:Intelligence / Q000187:drug effects; D008939:Mitotane / Q000008:administration & dosage / Q000009:adverse effects*; D009460:Neurologic Examination / Q000187:drug effects*; D009483:Neuropsychological Tests; D011597:Psychomotor Performance / Q000187:drug effects; D012021:Reflex, Abnormal / Q000187:drug effects; D019966:Substance-Related Disorders / Q000175:diagnosis*
D008939:Mitotane